EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT

Matthew F Covington, Samantha Salmon, Andrew Kozlov, Zane Archibald, Regan Butterfield, Sophie Stolk, Sam Mitchell, Kenneth Boucher, Regina Rosenthal, Jane Porretta, Kirstyn E Brownson, Cindy Matsen und 7 weitere

Clinical Breast Cancer · 2026-01 · 26 (1) · 36-46

DOI: 10.1016/j.clbc.2025.11.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026-01. Verfasst von Matthew F Covington und 18 weiteren Autor:innen. Beteiligte Einrichtung: Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, UT; Department of Radiology and Imaging Sciences, University of Ut…. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron Emission Tomography Computed Tomography, Carcinoma, Lobular, Estradiol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Huntsman Cancer Foundation, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Invasive lobular carcinoma (ILC) often presents diagnostic challenges on conventional imaging, necessitating advanced imaging strategies for accurate staging. [18F]Fluoroestradiol (FES), a PET radiopharmaceutical, targets estrogen receptor-positive (ER+) lesions, which are prevalent in ILC. This study evaluates the utility of FES-PET/CT compared to standard-of-care (SOC) imaging for staging ER+ ILC. PATIENTS AND METHODS: This IRB-approved prospective trial (October 2022-October 2024) enrolled adults with histologically confirmed ER+ ILC at a National Cancer Institute-designated Comprehensive Cancer Center. Participants underwent FES-PET/CT, with optional [18F]Fluorodeoxyglucose (FDG)-PET/CT. The primary endpoint was the percentage of stage changes post-FES-PET/CT compared to SOC imaging, analyzed using a 1-sided binomial proportions test. Imaging was interpreted by a blinded nuclear and breast radiology specialist, with staging per AJCC eighth edition guidelines. RESULTS: Of 27 enrolled participants, 25 underwent FES-PET/CT (2 excluded due to synthesis failure). Mean age was 60.3 years. Pre-FES-PET/CT staging was stage I (16%), II (60%), III (20%), and IV (4%). FES-PET/CT altered clinical staging in 32% of cases (P = .036), identifying occult stage IV disease in 12.5% and histologically confirmed axillary lymph node metastases in 8%. However, it missed axillary metastases in 28% compared to surgical staging. FDG-PET/CT, performed in 15 participants, showed 40% discordance with FES-PET/CT. CONCLUSION: FES-PET/CT significantly enhances staging accuracy for ER+ ILC, detecting occult metastases that impact clinical management. Its limitations in axillary nodal detection suggest it complements, rather than replaces, surgical staging. Larger trials are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPositron Emission Tomography Computed TomographyCarcinoma, LobularEstradiolHumansFemaleProspective StudiesMiddle AgedNeoplasm StagingAgedFluorodeoxyglucose F18RadiopharmaceuticalsAdultReceptors, EstrogenLymphatic Metastasis

Stichwörter der Autor:innen

Breast cancer stagingER-positiveFESFluoroestradiolPET imaging

Substanzen

Fluorodeoxyglucose F18EstradiolRadiopharmaceuticals16-fluoroestradiolReceptors, Estrogen

Autor:innen und Institutionen

  • Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, UT; Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT. Electronic address: Mcovington@spsradiology.co…
  • Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT.
  • Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, UT.
  • Division of Epidemiology, Huntsman Cancer Institute, Salt Lake City, UT.
  • Division of Surgical Oncology, Huntsman Cancer Institute, Salt Lake City, UT.
  • Division of Oncology, Huntsman Cancer Institute, Salt Lake City, UT.

Förderung

  • NCI NIH HHS
  • Huntsman Cancer Foundation
  • National Cancer Institute

Zitieren

APA

Covington, M. F., Salmon, S., Kozlov, A., Archibald, Z., Butterfield, R., Stolk, S., Mitchell, S., Boucher, K., Rosenthal, R., Porretta, J., Brownson, K. E., Matsen, C., Wei, M., Buys, S., Vaklavas, C., Chittoria, N., Buckway, B., Meite, A., & Yap, J. (2026). Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT. Clinical Breast Cancer, 26(1), 36-46. https://doi.org/10.1016/j.clbc.2025.11.003

Vancouver

Covington MF, Salmon S, Kozlov A, Archibald Z, Butterfield R, Stolk S, et al. Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT. Clinical Breast Cancer. 2026;26(1):36-46. doi:10.1016/j.clbc.2025.11.003

BibTeX
@article{Covington2026,
  author = {Covington, Matthew F and Salmon, Samantha and Kozlov, Andrew and Archibald, Zane and Butterfield, Regan and Stolk, Sophie and Mitchell, Sam and Boucher, Kenneth and Rosenthal, Regina and Porretta, Jane and Brownson, Kirstyn E and Matsen, Cindy and Wei, Mei and Buys, Saundra and Vaklavas, Christos and Chittoria, Namita and Buckway, Brandon and Meite, Angela and Yap, Jeffrey},
  title = {Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT},
  journal = {Clinical Breast Cancer},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {36--46},
  doi = {10.1016/j.clbc.2025.11.003}
}
Kostenlos starten →